bioRxiv Science⌕ Search

Biology subjects

Chasse, M. H.

Publications and source records attributed to Chasse, M. H..

2 recordsLinked to original sources

An attractor state zone precedes neural crest fate in melanoma initiation

Field cancerization posits that groups of cells harboring oncogenic mutations create a permissive landscape predisposed to malignant transformation. We previously identified rare single cells in BRAFV600E;p53-/- zebrafish that reactivate an embryonic neural crest program prior to melanoma initiation. Here, we identify a specific field of BRAFV600E;p53-/-melanocytes with altered differentiation, morphology and cell-cycle regulatory programs that predates the neural crest activation. Based on single cell analysis, these cells form a cancer precursor zone (CPZ) from which a single clone ultimately stabilizes a neural crest-like state and expands to form melanoma. Using in vivo cellular barcoding combined with single-cell RNA-seq and ATAC-seq, we identify a transcriptionally distinct attractor state specific to oligoclonal CPZs that is modulated by BMP signaling. Mechanistically, BMP-dependent induction of the transcriptional repressor ID1 sequesters TCF12, thereby inhibiting lineage-specific targets required for maintenance of melanocyte identity and for clonal selection. Single cells from the CPZ initiate neural crest reprogramming and become tumorigenic. Analysis of a large human patient cohort reveals high ID1 expression in precursor melanocytes as early as dysplastic nevi and atypical melanocytic proliferations, implicating ID1 in early human melanomagenesis. This work identifies BMP signaling and ID1 as early, targetable vulnerabilities with potential for improved diagnosis and prevention of melanoma. Together, these findings uncover a previously unrecognized field effect during melanoma initiation, in which tumors emerge from an oligoclonal attractor-state zone of morphologically distinct yet clinically covert precursor cells with a defined altered transcriptional fate.

cancer biology↗

Direct therapeutic targeting of SWI/SNF induces epigenetic reprogramming and durable tumor regression in rhabdoid tumor

PurposeRhabdoid tumor is a pediatric cancer characterized by the biallelic inactivation of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. SMARCB1 inactivation leads to SWI/SNF redistribution to favor a proliferative dedifferentiated cellular state. Although this deletion is the known oncogenic driver, SWI/SNF therapeutic targeting remains a challenge. Experimental DesignWe define a novel epigenetic mechanism for mithramycin using biochemical fractionation, chromatin immunoprecipitation sequencing (ChIP-seq), and a dual spike-in assay for transposase accessible chromatin sequencing (ATAC-seq). We correlate epigenetic reprogramming with changes with chromatin A/B compartments and promoter accessibility with chromHMM models and RNA-seq. Finally, we demonstrate durable, marked tumor response in an intramuscular rhabdoid tumor xenograft model. ResultsHere we show mithramycin and a second-generation analogue EC8042 evict mutated SWI/SNF from chromatin and are effective in rhabdoid tumor. SWI/SNF blockade triggers chromatin compartment remodeling and promoter reprogramming leading to differentiation and amplification of H3K27me3, the catalytic mark of PRC2. Treatment of rhabdoid rumor xenografts with EC8042 leads to marked, durable tumor regression and differentiation of the tumor tissue into benign mesenchymal tissue, including de novo bone formation. ConclusionOverall, this study identifies a novel therapeutic candidate for rhabdoid tumor and an approach that may be applicable to the 20% of cancers characterized by mutated SWI/SNF. STATEMENT OF TRANSLATIONAL RELEVANCEThere is a tremendous need for novel therapeutic approaches for rhabdoid tumor and the more than 20% of human cancers characterized by dysregulation of the SWI/SNF chromatin remodeling complex. While approaches to target associated complexes, such as PRC2, known to be influenced by dysregulated SWI/SNF are currently being evaluated in the clinic, the direct therapeutic targeting of SWI/SNF has not been explored. Here we identify an inhibitor of SWI/SNF and thoroughly explore the therapeutic development of this compound from a mechanistic and translational perspective thus providing insight into the targeting of this complex as well as a dose, schedule, and biomarker of target inhibition that is immediately clinically translatable.

cancer biology↗